Results from the first 15 patients in a Phase IIA trial with Bone Therapeutics’ ALLOB® show evidence of successful spinal fusion and statistically significant improvements at 12 months.
The trial is evaluating the use of ALLOB allogeneic cell therapy along with the standard of care: implantation of an interbody cage + bioceramic granules.
X-rays indicated an absence of motion at treated levels in all 15 patients at 12 months, and statistically significant improvement in function from baseline, as well. Further, back and leg pain were reduced by 59% and 90%, respectively.
To support a focus on this study’s data, Bone Therapeutics will halt recruitment for its exploratory study in rescue treatments for failed spinal fusion and close that study once follow-up is complete.
Results from the first 15 patients in a Phase IIA trial with Bone Therapeutics' ALLOB® show evidence of successful spinal fusion and statistically significant improvements at 12 months.
The trial is evaluating the use of ALLOB allogeneic cell therapy along with the standard of care: implantation of an interbody cage + bioceramic granules. ...
Results from the first 15 patients in a Phase IIA trial with Bone Therapeutics’ ALLOB® show evidence of successful spinal fusion and statistically significant improvements at 12 months.
The trial is evaluating the use of ALLOB allogeneic cell therapy along with the standard of care: implantation of an interbody cage + bioceramic granules.
X-rays indicated an absence of motion at treated levels in all 15 patients at 12 months, and statistically significant improvement in function from baseline, as well. Further, back and leg pain were reduced by 59% and 90%, respectively.
To support a focus on this study’s data, Bone Therapeutics will halt recruitment for its exploratory study in rescue treatments for failed spinal fusion and close that study once follow-up is complete.
Copy to clipboard 
